Acceder

Publicaciones - TRASPLANTE HEMATOPOYÉTICO / TERAPIA CELULAR

Cargando...
Hofmann N, Lafarge X, Antica M, Ferry N, Girandon L, Gramignoli R, Jurga M, Kerdjoudj H, Navakauskiene R, Schiavi J, Shablii V, Nicolas FJ, Gindraux F. Expert Consideration on Regulatory Aspects for Perinatal Derivatives in Clinical Settings. Stem Cells Transl Med. 2023 May 15;12(5):258-265. doi: 10.1093/stcltm/szad017. PubMed PMID: 37027834; PubMed Central PMCID: PMC10184691.
AÑO: 2023; IF: 6.0
37027834
Rodriguez-Lozano FJ, Lopez-Garcia S, Sanchez-Bautista S, Perez-Lopez J, Raigrodski AJ, Revilla-Leon M. Effect of milled and lithography-based additively manufactured zirconia (3Y-TZP) on the biological properties of human osteoblasts. J Prosthet Dent. 2023 Dec;130(6):889-896. doi: 10.1016/j.prosdent.2022.01.025. Epub 2022 Mar 6. PubMed PMID: 35264309.
AÑO: 2023; IF: 4.6
35264309
Pinana JL, Vazquez L, Calabuig M, Lopez-Corral L, Martin-Martin G, Villalon L, Sanz-Linares G, Conesa-Garcia V, Sanchez-Salinas A, Gago B, Facal A, Risco-Galvez I, Olave MT, Espigado I, Lopez-Jimenez J, Hernandez-Rivas JA, Avendano-Pita A, Arroyo I, Ferrer E, Garcia-Cadenas I, Gonzalez-Santillana C, Roldan-Perez A, Ferrer B, Guerreiro M, Suarez-Lledo M, Camara A, Campos-Beltran D, Navarro D, Cedillo A, Sureda A, Solano C; Spanish Hematopoietic Stem Cell Transplantation and Cell Therapy Group (GETH-TC); Martino R. One-year breakthrough SARS-CoV-2 infection and correlates of protection in fully vaccinated hematological patients. Blood Cancer J. 2023 Jan 5;13(1):8. doi: 10.1038/s41408-022-00778-3. PubMed PMID: 36599843; PubMed Central PMCID: PMC9812742.
AÑO: 2023; IF: 12.8
36599843
Luciano AM, Di Martile M, Perez-Oliva AB, Di Caprio M, Foddai ML, Buglioni S, Mulero V, Del Bufalo D. Exploring association of melanoma-specific Bcl-xL with tumor immune microenvironment. J Exp Clin Cancer Res. 2023 Jul 24;42(1):178. doi: 10.1186/s13046-023-02735-9. PubMed PMID: 37488586; PubMed Central PMCID: PMC10364435.
AÑO: 2023; IF: 11.3
37488586
Lakhwani S, Rosinol L, Puig N, Pico-Picos MA, Medina-Gonzalez L, Martinez-Lopez J, Paiva B, Cedena MT, Oriol A, Rios-Tamayo R, Blanchard MJ, Jarque I, Bargay J, Moraleda JM, Carrillo-Cruz E, Sureda A, Krsnik I, Gonzalez E, Casado LF, Marti JM, Encinas C, De Arriba F, Palomera L, Sampol A, Gonzalez-Montes Y, Motllo C, De La Cruz J, Alonso R, Mateos MV, Blade J, Lahuerta JJ, San-Miguel J, Hernandez MT. Recovery of uninvolved heavy/light chain pair immunoparesis in newly diagnosed transplant-eligible myeloma patients complements the prognostic value of minimal residual disease detection. Haematologica. 2023 Nov 30. doi: 10.3324/haematol.2023.284154. Online ahead of print. PubMed PMID: 38031761.
AÑO: 2023; IF: 10.1
38031761
< AnteriorSiguiente >
IMIB-Arrixaca

Instituto de Investigación Sanitaria Acreditado

ISCII

TRASPLANTE HEMATOPOYÉTICO / TERAPIA CELULAR